Linked Life Data

20188526

Source:http://linkedlifedata.com/resource/pubmed/id/20188526

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-4-19
pubmed:abstractText
Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1872-7913
pubmed:author
pubmed:copyrightInfo
2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
524-6
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!
pubmed:affiliation
Unit of Mycobacteriology/UPMM, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal. lamaral@ihmt.unl.pt
pubmed:publicationType
Journal Article, Review